Target Audience

The intended audience for the activity is retina specialists and other health care professionals involved in the treatment of patients with retinal diseases.

Program Overview

The meeting will be a forum for interaction, with ground-breaking content spanning medical and surgical retina, as well as imaging and practice management. Standards and best practices will be shared with a focus on content that is practical and immediately applicable. You’ll have the opportunity to expand your knowledge through case studies, panels, surgical videos, and the latest in clinical trials. You can also participate in interactive sessions designed to maximize learning for all participants and a reception where you can mingle with faculty and colleagues.

The following topics will be covered throughout the program:

  • Macular Surgery
  • Medical Retina: Retina Vein Occlusion
  • Trauma and Proliferative Vitreoretinopathy Surgery
  • Surgical Technology
  • Retinal Detachment Surgery
  • Imaging
  • Age-related Macular Degeneration
  • Diabetic Vitrectomy
  • Ocular Oncology
  • Pediatrics, Pediatric Surgery and Gene Therapy
  • Controversies and Debates
  • Medical Retina: Diabetic Macular Edema and Diabetic Retinopathy
  • RETINAWS
  • Uveitis
  • First-time Presentations of Clinical Trials and Late Breakers

Learning Objectives: General Sessions

After completing this activity, the participant should be better able to:

  • Review the latest clinical trial data and treatments in clinical trials relevant to retinal disorders
  • Identify new technologies that may reduce treatment burden for patients with retinal vascular disease
  • Evaluate new imaging technologies that can improve retinal disease detection and better assess patient responses to therapy
  • Identify advantages and disadvantages of combination therapies for the treatment of neovascular age-related macular degeneration (AMD)
  • Explain the mechanism of action, ongoing clinical trial designs, and advantages and disadvantages of new therapies being developed for the treatment of diabetic retinopathy (DR)
  • Assess novel management strategies in treating patients with diabetic retinopathy
  • Describe the latest clinical trial data, patient outcomes, and emerging treatments for diabetic macular edema (DME)
  • Recall the latest clinical trial data and management strategies for retinal vein occlusion
  • Recognize side effects of commonly used uveitis treatments, and optimize management of patients who develop these side effects
  • Summarize key clinical study findings for new treatment options being developed for the treatment of uveitis
This continuing medical education activity is provided by

Retina World Congress 2019 is supported, in part, by independent educational grants from Allergan, Inc. and Regeneron Pharmaceuticals, Inc.

ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 23.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INTERNATIONAL NOTICE: This educational activity is designated for AMA PRA Category 1 Credit(s)™ for all US physicians. US physicians will receive a CME certificate and non-US physicians should contact their respective organizations for reciprocity of credit.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all planners, teachers and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.